Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Brumm

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
Annals of Neurology|December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein DiseaseEthan G Brown, Lana M Chahine, Andrew Siderowf, et al.
Annals of Clinical and Translational Neurology|December 15, 2020
Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorderLana M Chahine, Michael C Brumm, Chelsea Caspell-Garcia, et al.
Annals of Neurology|July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior DisorderDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Brain Communications|March 21, 2025
<i>LRRK2</i>-associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
LRRK2-Associated Parkinsonism With and Without <i>In Vivo</i> Evidence of Alpha-Synuclein AggregatesLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
NPJ Parkinson'S Disease|September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
Annals of Neurology|December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein DiseaseEthan G Brown, Lana M Chahine, Andrew Siderowf, et al.
Annals of Clinical and Translational Neurology|December 15, 2020
Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorderLana M Chahine, Michael C Brumm, Chelsea Caspell-Garcia, et al.
Annals of Neurology|July 11, 2025
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior DisorderDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Brain Communications|March 21, 2025
<i>LRRK2</i>-associated parkinsonism with and without <i>in vivo</i> evidence of alpha-synuclein aggregates: longitudinal clinical and biomarker characterizationLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2020
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional StudyTanya Simuni, Michael C Brumm, Liz Uribe, et al.
Medrxiv : the Preprint Server for Health Sciences|August 7, 2024
LRRK2-Associated Parkinsonism With and Without <i>In Vivo</i> Evidence of Alpha-Synuclein AggregatesLana M Chahine, David-Erick Lafontant, Seung Ho Choi, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
NPJ Parkinson'S Disease|September 27, 2024
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Medrxiv : the Preprint Server for Health Sciences|September 24, 2024
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohortsTien Dam, Gennaro Pagano, Michael C Brumm, et al.
Pageof 9